Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Silexion Therapeutics Corp

SLXN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.23

▼ -7.37%

Market Cap $3.40M · Vol 93.75K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.40M

Micro Cap

Div Yield

N/A

EPS Growth

+94.75%

YoY

RSI (14)

32.71

Momentum

Beta

-0.37

vs Market

52W High

$40.60

99.42% below

52W Low

$0.22

4.87% above

Volume

93.75K

Avg 715.39K

P/B

2.31

Price-to-book

ROE

N/A

Return on equity

Free Float

85.33%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Silexion Therapeutics Corp (SLXN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SLXN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.81%

-31.89%

-91.10%

-97.90%

YTD

-98.78%

-99.41%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,912,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-236.34% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.31
P/FCF	N/A
EPS Growth	+94.75%
Outstanding Shares	14.47M

Technical Indicators

50-Day SMA	$0.60
200-Day SMA	$8.39
RSI (14)	32.71
Beta	-0.37
52-Week High	$40.60
52-Week Low	$0.22

Volume Today	93.75K
Avg Daily Volume (30D)	715.39K
Relative Volume	0.13x
Volatility (10D)	154.25
Volatility (30D)	196.54
Free Float	85.33%

Analyst Consensus

BUY

Current Price $0.23

Mean Target $5.00

52W Low$0.22 52W High$40.60

Current

Target

$0.22 $40.60

Current Analyst target

+2,028.57% upside potential · 2 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01PBJB8F3

ISINKYG1281K1489

CountryIsrael

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -4.30% ARGX.BR argenx SE -15.86% ARGX argenx SE -11.83% 2269.HK WuXi Biologics (Cayman) Inc. -4.59% GMAB Genmab A/S -1.64%

Company Profile

Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.